Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase RNF152 (RNF152) is a small, lysosome-localized, single-pass transmembrane RING finger protein with E3 ubiquitin ligase activity[1][2][3][6]. RNF152 is best known for its role as a negative regulator of the mTORC1 signaling pathway: under conditions such as amino acid starvation or absence of growth factors, it ubiquitinates small GTPases (e.g., RagA via K63-linked polyubiquitination, Rheb via monoubiquitination), thereby inhibiting mTORC1 activity and regulating cell growth and proliferation[3][6]. RNF152 also self-ubiquitinates, which regulates its own degradation[2]. Beyond mTORC1 regulation, RNF152 can suppress Wnt/β-catenin signaling and modulate inflammatory and developmental pathways, including neural crest formation and innate immune signaling—actions that can be dependent or independent of its enzymatic ligase activity[2]. Overexpression promotes apoptosis, making RNF152 functionally relevant to cell death, cancer, and possibly neurodegeneration[1][3]. It is associated with diseases including cancer, neurodegenerative diseases, and developmental disorders[3][5]. The identification and targeting of RNF152 is of growing interest for therapies modulating mTORC1- or Wnt-dependent pathologies.
Negative regulation of mTORC1 activity through ubiquitination of GDP-bound RagA (via K63 linkage) and GDP-bound Rheb (monoubiquitination), leading to inhibition of mTORC1 signaling[3][6] - Negative regulation of Wnt/β-catenin pathway by inhibiting Dishevelled polymerization (in some contexts, independent of ligase activity)[2] - Modulation of inflammatory signaling by facilitating MyD88 oligomerization (E3 activity-independent)[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase RNF152 (RNF152).